The U.S. Food and Drug Administration (FDA) has granted a significant approval to Biogen (BIIB) and Eisai’s (ESALF) (ESAIY) Leqembi Iqlik (lecanemab). This regulatory decision introduces a subcutaneous version of their Alzheimer’s treatment, Leqembi, marking an important development in the therapeutic options available for patients.
Leqembi Iqlik has received specific clearance for administration across the entire treatment spectrum, encompassing both initiation and maintenance dosing. A critical component of this approval is the authorization for the subcutaneous version to be used in at-home settings. This dual capability for flexible dosing and home administration is anticipated to enhance patient convenience and potentially broaden access to this vital Alzheimer’s therapy.
This milestone provides Biogen and Eisai with an expanded and more adaptable delivery method for lecanemab. The availability of an at-home, subcutaneous option for both starting and continuing treatment represents a strategic evolution in patient care, aiming to streamline the therapeutic process for individuals managing Alzheimer’s disease.
